Andrew Baum, Pfizer's chief strategy and innovation officer, talked Thursday about the pharmaceutical company's drug ...

Both deputy directors at the key FDA center that oversees regulation of cancer drugs plan on leaving the agency ...

Pfizer's stock is poised for growth due to its strong pipeline, smart cost management, and recovery from COVID-19 revenue ...

There’s no question, however, that the decision to abandon the twice-daily version introduces a significant delay to Pfizer’s plans to enter the obesity market, which has been transformed in ...

The anticipation surrounding dose optimization data for Pfizer's obesity treatment ... due to the study's structure and disclosure plans. With a solid financial health score of "GOOD" from ...

Pfizer (NYSE:PFE) is undervalued, trading well below its historical and sector averages despite strong non-COVID revenue growth and cost optimizations. Its expanding pipeline in oncology, obesity ...

In vaccines, Pfizer plans to start a Phase 3 study for PCV ... study is critical for Pfizer’s entry into the lucrative obesity market. It is still in progress, with data expected in Q1-CY25.

Pfizer and partner ... loss of 25%. NVO plans to file regulatory applications seeking approval for CagriSema in the first quarter of 2026. Roche Buys Rights to Obesity Drug from Zealand Pharma ...

For Lilly, the main driver behind LillyDirect has been seen as Zepbound, which, as an obesity drug ... market battle with GSK's Arexvy. Pfizer has said it plans to expand the medicines and ...

List will oversee Pfizer’s Internal Medicine portfolio and will be responsible for advancing the company’s emerging pipeline of cardiovascular, metabolic, hematologic, and obesity medicines.

In his first public comments, Pfizer’s new innovation chief — once a Wall Street analyst skeptical of the company — said he was confident in the company’s obesity plans and shed light on ...

Pfizer (NYSE:PFE) is undervalued, trading well below its historical and sector averages despite strong non-COVID revenue growth and cost optimizations. Its expanding pipeline in oncology, obesity ...